#NewResearch – “Intratumoral heterogeneity and immunotherapy resistance: clinical implications” Read more: https://t.co/hmjYBt7TTc

Results from this multicenter, randomized, open-label phase 2 study demonstrated that subjects who received tailored treatment over standard of care achieved significantly higher overall response rate and improved progression-free survival. More here:

A recent investigator-initiated study utilized Foundation Medicine’s tissue- & blood-based comprehensive genomic profiling to identify actionable alterations: “Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial”: https://t.co/hU3ZtTos7k

We are proud to support @LUNGevity's Cancer Precision Medicine Commons to further raise awareness and education around biomarker testing this #CancerBiomarkerDay. Click here for more information and resources: https://t.co/7Nmkg3s3d4

Our latest webinar with @PrecMedOnline will focus on the evolving landscape of biomarker-genomic treatment for advanced non-small cell #lungcancer (NSCLC). Join us for this expert-led conversation – register today: https://t.co/OgPueuJbae

Explore #NewResearch🔬 published in @CRC_AACR: “Succinate dehydrogenase B (SDHB) overexpression with enzymatic dysfunction defines a distinct subtype of undifferentiated pleomorphic sarcoma.” Click here for more: https://t.co/0065DczRhk

Let’s connect at #AMP25! We’ll be discussing our new molecular residual disease (MRD) test for research use and other #PrecisionMedicine innovations at our corporate workshop and booth 320. Schedule time to meet:

Heading to #AMPath25 November 11-15? Stop by booth 320 to meet our team and see how Foundation Medicine maximizes tissue biopsies with our low QNS rate. Discover what makes our portfolio different!

Foundation Medicine will be at #AMPath25 at booth 320! Schedule time to explore solutions that help deliver deeper #genomic insights and more actionable results: https://t.co/HOKPQfmbOO

Honoring #LungCancer Awareness Month this November and all those within our community and beyond who have been impacted by the disease. Follow us this month for patient stories, resources and more.

Attending the meeting? Visit us at booth 201 or schedule time with our team:

At #ISLB25, our team is proud to present new #research, including the oral presentation “Circulating tumor DNA (ctDNA) detectable in buffy coat DNA (bcDNA) can resemble clonal hematopoiesis with potential biological and clinical implications”

We’re proud to collaborate with Manifold, the AI data platform for life sciences, to bring enhanced analytics capabilities to our FoundationInsights® platform. Learn more: https://t.co/bOEUdJxg1c

What is a companion diagnostic? How does it work? And what are the benefits? Explore more in our latest Precision Points Blog “Companion Diagnostic Explained”: https://t.co/1ocezoRoR9

Schedule time with our team at #ISLB25 and learn more at the link here:

Join us at #ISLB25 – November 1-3. Meet our team at booth 201 to learn more about how Foundation Medicine and our FDA-approved #LiquidBiopsy test provides information that can help physicians determine treatment paths for their patients with advanced cancer.

Hear from experts through a series of webinars on the importance of biomarker testing, specifically comprehensive genomic profiling, in #BreastCancer treatment and care. Explore our “Pioneers in Practice – Breast Series” at the link here:

#NewResearch publication in @NatureGenet – “Meta-analysis reveals differences in somatic alterations by genetic ancestry across common cancers.” Learn more: https://t.co/BEbubxodre

Learn more about the research being presented:

Visit us at booth 3028 in Hall 3.2! Discover more and connect with our team at this year’s meeting: